Cargando…

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement

Dengue fever is a global health threat caused by the dengue virus (DENV), a vector-borne and single-stranded RNA virus. Development of a safe and efficacious vaccine against DENV is a demanding challenge. The greatest pitfall in the development of vaccines is antibody-dependent enhancement (ADE), wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qier, Li, Rong, Wu, Bolin, Zhang, Xu, Zhang, Hui, Chen, Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235449/ https://www.ncbi.nlm.nih.gov/pubmed/37275868 http://dx.doi.org/10.3389/fimmu.2023.1193175

Ejemplares similares

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
por: Ambuel, Yuping, et al.
Publicado: (2014)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Erratum: A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
Publicado: (2014)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine
por: Tsuji, Isamu, et al.
Publicado: (2021)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
por: Basheer, Amina, et al.
Publicado: (2023)

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice
por: Aggarwal, Charu, et al.
Publicado: (2023)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
por: Metz, Stefan W., et al.
Publicado: (2018)

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine
por: Lin, Tsung-Han, et al.
Publicado: (2020)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine
por: Byers, Anthony M., et al.
Publicado: (2015)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes
por: Li, Leike, et al.
Publicado: (2019)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort
por: Silveira, Cássia G. T., et al.
Publicado: (2022)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity
por: Zhang, Wei, et al.
Publicado: (2018)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice
por: Tao, Yuyong, et al.
Publicado: (2019)

Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients
por: Moser, Tobias, et al.
Publicado: (2021)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity
por: Qi, Zhongbing, et al.
Publicado: (2023)

Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
por: Wang, Ran, et al.
Publicado: (2020)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
por: Yang, Zheng, et al.
Publicado: (2018)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement
por: Sarker, Animesh, et al.
Publicado: (2023)

Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
por: Chan, Yanqi, et al.
Publicado: (2020)

Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies
por: Powell, Abigail E., et al.
Publicado: (2022)

Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
por: Prompetchara, Eakachai, et al.
Publicado: (2014)

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
por: Chen, Xin, et al.
Publicado: (2022)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a45a8pg8d5rnek0u0uq75627u2